NCT07322016招募中1 期
A Single-dose, Open-label Phase I Clinical Trial Comparing the Pharmacokinetics, Safety and Pharmacodynamics of HRS-1301 Tablets in Subjects With Mild, Moderate and Severe Renal Insufficiency and Healthy Subjects
Shandong Suncadia Medicine Co., Ltd.1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2026年1月13日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Maximum concentration (Cmax).
研究概览
简要总结
The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Sign the informed consent before the trial, and fully understand the content, process, and possible adverse reactions of the trial;
- •Male or female subjects aged 18 to 65 (including 18 and 65);
- •Body mass index (BMI) ranges from 18 kg/m2 to 30 kg/m2 (including 18 and 30),and Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg;
- •The glomerular filtration rate should meet the following criteria (GFR, mL/min): Subjects with mild renal impairment: 60-89 mL/min; Subjects with moderate renal impairment: 30-59 mL/min; Subjects with severe renal function impairment: 15~29 mL/min.
排除标准
- •Individuals with a specific history of allergies (such as asthma, urticaria, eczema, etc.), or those with an allergic constitution (such as those allergic to any drug or food), or those known to be allergic to any component of the studied drug;
- •Those with cardiogenic shock, severe conduction obstruction, sick sinus syndrome, heart failure (NYHA grade III-IV), persistent rapid arrhythmia, tortuous ventricular tachycardia or ventricular tachycardia at the pointed point, a history of clinically significant T-wave changes, myocardial infarction, or angina pectoris;
- •Suffering from malignant tumors, or having a history of malignant tumors within 5 years prior to screening (excluding skin non-melanomas that have been treated without recurrence signs and resected cervical intraepithelial neoplasia);
- •Those with a history of gastric or intestinal surgery that some researchers believe may affect drug absorption;
- •Those who have suffered severe trauma or undergone major surgical operations within the three months prior to screening, or who plan to undergo surgery during the trial period;
- •Those who have participated in any clinical trials of drugs or medical devices within three months prior to screening, or those who are still within five half-lives of the drug before screening (whichever is longer);
- •Those who have donated blood of ≥ 400 mL within 4 weeks before screening, or have suffered severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within 8 weeks;
- •Those who received live (attenuated) vaccines within 4 weeks prior to screening or those who plan to receive them during the trial;
- •Those with potential difficulties in blood collection and a history of fainting at the sight of needles or blood;
- •For patients with renal insufficiency,those who have received renal replacement therapy (such as peritoneal dialysis, hemodialysis, etc.) within 3 months prior to the screening or during the expected trial period;
- •For patients with renal insufficiency，screening individuals with underlying diseases that induce chronic kidney disease within the previous three months and are judged by researchers to be poorly controlled, such as diabetic patients with HbA1c > 10%, and hypertensive patients with systolic blood pressure > 180 mmHg and diastolic blood pressure > 120 mmHg, etc.
研究组 & 干预措施
HRS-1301 Tablet Group
Experimental
Treatment for oral medication.
干预措施: HRS-1301 Tablet (Drug)
结局指标
主要结局
Maximum concentration (Cmax).
时间窗: 0 hour to 8 days after dosing.
Pharmacokinetic parameters of HRS-1301 in plasma.
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last).
时间窗: 0 hour to 8 days after dosing.
Pharmacokinetic parameters of HRS-1301 in plasma.
Area under the concentration-time curve from time zero to infinity (AUC0-inf).
时间窗: 0 hour to 8 days after dosing.
Pharmacokinetic parameters of HRS-1301 in plasma.
次要结局
- Time of maximum concentration (Tmax).(0 hour to 8 days after dosing.)
- Area under the concentration-time curve from time zero to the end of the dosing interval tau (AUC0-tau).(0 hour to 8 days after dosing.)
- Elimination half-life (t1/2).(0 hour to 8 days after dosing.)
- Apparent clearance (CL/F).(0 hour to 8 days after dosing.)
- Apparent volume of distribution (Vz/F).(0 hour to 8 days after dosing.)
- Cumulative drug excretion in urine (Ae,urine).(0 hour to 6 days after dosing.)
- Cumulative drug excretion fraction in urine (fe,urine).(0 hour to 6 days after dosing.)
- Incidence of adverse events (AEs).(0 hour to 8 days after dosing.)
- Incidence of serious adverse events (SAEs).(0 hour to 8 days after dosing.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy VolunteersType 2 DiabetesNCT07304700Chong Kun Dang Pharmaceutical30
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy VolunteersType 2 DiabetesNCT07304726Chong Kun Dang Pharmaceutical30
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy VolunteersType 2 DiabetesNCT07304687Chong Kun Dang Pharmaceutical31
招募中
2 期
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous NephropathyNCT07289763Guangdong Hengrui Pharmaceutical Co., Ltd75
已完成
1 期
A Clinical Study of RSS0343 in Healthy SubjectsNCT07289464Reistone Biopharma Company Limited48